Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fiasp vs NovoLog in Medtronic 670G System for T1D
NCT03977727Phase 3Completed
- Sponsor
- Texas Diabetes and Endocrinology
- Start
- Jun 2019
- Primary completion
- Mar 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of human insulin in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Texas Diabetes and Endocrinology. Primary endpoint: 1-Hour Change in Postprandial Plasma Glucose at 6 weeks. Started Jun 2019; status: completed.
02
Drugs
human insulin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03977727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03977727.